ClinicalTrialsFinder
RecruitingPhase 2NCT07488117

Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

Sponsor

University Hospital, Toulouse

Enrollment

40 participants

Start Date

Mar 31, 2026

Study Type

INTERVENTIONAL

Conditions

Autoimmune Encephalitis (AE)

Summary

This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying TEP with radioligand EAI 714 for people with autoimmune encephalitis (ae). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTEP with radioligand EAI 714

60-minutes \[18F\]-DPA-714 PET imaging

Locations(1)

University Hospital

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07488117

Related Trials

A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults

NCT07583641

Plasma Exchange in Pediatric Autoimmune Encephalitis

NCT07707739

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

NCT073377851 location

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

NCT075264931 location